In 2022, the Biopharma industry saw groundbreaking advances in several areas like - RNA therapeutics, gene editing, ADCs, LAG-3 inhibitors, and TYK-2 inhibitors
AHMEDABAD, GUJARAT, INDIA, March 14, 2023
/EINPresswire.com/ -- “Top 10 Life sciences trends in 2022”, a research report released recently by Healthark Insights focuses on the top trends that are shaping the future of the biopharma industry, amongst various innovations that are happening in the life sciences domain.
The Healthark Insights team tracked and captured 100+ significant trends in the life sciences and biopharma industry in 2022.
Biopharma is set to witness one of the biggest patent cliffs with several blockbuster drugs undergoing loss of exclusivity from 2023-2028, totaling around $200B in revenue loss” — Dr. Purav Gandhi
We gathered key information for each trend such as focus area, novelty, lucrativeness, market interest, commercialization, etc. to understand the larger impact potential of each trend. Each trend was then given a weightage and rating based on two key criteria – (i) impact on the future of health and, (ii) ease of commercialization. The top 10 trends were identified on their scores and were analyzed further to understand their potential to bring about disruption in the Life Sciences industry.
Several emerging and novel therapies buzzed throughout the year 2022. RNA therapeutics, Gene editing, and ADC therapeutics garnered a lot of attention from biopharma, whereas novel therapies such as LAG-3 inhibitors and TYK-2 inhibitors came into the spotlight with first-in-class approvals in 2022.
RNA therapeutics with 850+ assets in the clinical pipeline in 2022 and increasing collaborations between big pharma and biotech have become an attractive class for the industry. Gene editing, on the other hand, gained sudden popularity after the pandemic with pouring investments and intense pipelines across a range of therapy areas. Antibody-drug conjugates (ADC) famously known as the magic bullet in cancer, after two decades of trial and error in R&D, have once again picked up interest from the industry and are poised to deliver a plethora of targeted drugs to treat a wide range of tumor types.
TYK2 inhibitors, a new class from the JAK family, is a promising avenue in immunology and have drawn the biopharma sector’s eyeballs due to their better safety profile and the possibility of oral RoA. LAG-3 inhibitors are the potential next big checkpoint inhibitor target filling a complex role in the immune system. There are heavy clinical pipelines with 165 active clinical trials on 38 drugs that are targeting LAG-3. BMS is leading the race in both categories with its first product approvals in these novel categories - Sotyktu as TYK-2 inhibitor and Opdualag as LAG-3 inhibitor.
Biopharma is set to witness one of the biggest patent cliffs with several blockbuster drugs undergoing loss of exclusivity from 2023-2028, totaling around >$200B in revenue loss. Due to this, a biosimilar boom is expected in this decade, especially driven by biosimilars for Humira. Regulatory support is also increasing in this area, with CMS permitting the substitution of interchangeable biosimilars. Congress’ Biosimilar user fee act (BsUFA) reauthorization will increase access and adoption of biosimilars.
It is also important to note that despite relaxation from covid-19 pandemic, the interest in decentralized clinical trials (DCT) not only persists among the biopharma but has also increased globally. Takeda leads the DCT trials suite with 33% of its total clinical trials being DCT in 2022.
You can read more of such interesting insights on “Top 10 Life sciences trends of 2022” by visiting the Healthark Insights website.
About Healthark Insights Top 10 Research Report Series
Healthark Insights annually tracks the top events and trends in the healthcare and life sciences industry and publishes five reports at the end of each year summarizing the top 10 trends in the healthcare industry, life sciences industry, health tech, the top 10 innovations, and top 10 mergers & acquisitions, with an objective of summarizing the key events and industry-shaping forces during the previous year and shares a viewpoint on how the sector will evolve in the coming year.
Insights Healthark Insights is a global management consulting firm developed by a team of experts from diverse fields such as consulting, pharma, medicine, medical devices, digital health, public health, and management with a common vision to cater to the healthcare and life sciences industry, along with a relentless focus on delivering executable solutions.
Healthark Insights team helps customers make critical decisions every day through expertise that combines deep domain knowledge, rigorous research, and analysis, understanding of markets, technology, and experience. With the right experience and expertise, the team not only provides insights but also works closely with clients to execute the strategy that they have helped develop.
Healthark Wellness Solutions LLP
+91 91600 01292
email us here
Visit us on social media:
Top 10 Lifesciences Trends in 2022 - A video snapshot by Healthark Insights